The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhibitor development studies. Research on how best to switch concentrates with respect to dosing regimen are lacking, and currently a trial-and-error approach is used for dosing the new factor concentrate. In the future, studies looking at the predictability of pharmacokinetics (PK) of a new factor concentrate based on individual PK knowledge of the original factor concentrate may offer clinical benefit by providing a safer switching approach and protocol.
|Original language||English (US)|
|Number of pages||14|
|Journal||Research and practice in thrombosis and haemostasis|
|State||Published - Jul 2019|
Bibliographical noteFunding Information:
We thank Caitlin Carter, Librarian, School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada, for assistance with this scoping review.
- drug substitution
- factor IX
- factor VIII
- hemophilia A
- hemophilia B
PubMed: MeSH publication types
- Journal Article